60 UPCYCLED INGREDIENTS Nonelastic Skin Epidermis Firm and Elastic Skin


2.5 2


*


1.5 1


0.5 0


Control Dermis 2.0 5.0 10.0 Glucosyl naringin active (mg/mL)


Figure 3: Tropoelastin mRNA expression level treated with or without glucosyl naringin active relative to control. N=3, Mean + SD, *p<0.05, **p<0.01 vs. control (Dunnett’s test)


** 150 Degraded Elastin fibre Figure 2: Elastin function for skin elasticity


The elastin fibres intricately bundle collagen fibres, providing elasticity and resilience to the skin (Figure 2). However, elastin fibres are known to


decrease and degenerate with ageing and photo-ageing, breaking down the network structure of collagen fibres, and resulting in loss of firmness and elasticity. Although injectable fillers, such as


collagen and hyaluronic acid injections, have been developed to rejuvenate the skin, elastin fillers are currently little known since the formation of elastin fibres is complex and involves in multiple processes. Therefore, glucosyl naringin active, which promotes the formation of elastin fibres, could be a reviving solution for consumers seeking a youthful appearance.


Control A


35 30 25 20 15 10 5 0


**


Results Effects on quantity: enhancement of elastin production Tropoelastin is a major component of elastin, and its expression decreases by ageing.4 Firstly, the effect on tropoelastin mRNA expression in normal human dermal fibroblasts (NHDF) were investigated. NHDF were incubated with or without 2.0, 5.0, 10.0 mg/mL of glucosyl naringin active (Glucosyl Naringin, Hayashibara). After 48 hours incubation, it significantly up


regulated the tropoelastin mRNA expression in a dose dependent manner (Figure 3). Then, to investigate the effects on elastin protein production, NHDF were incubated for 5 days with or without 1.0, 10.0 mg/mL glucosyl naringin active. The amount of elastin in NHDF


0.5mg/mL glucosyl naringin active 5.0mg/mL glucosyl naringin active 50 0 Control Collagen Fibroblast Elastin fibre 100 ** **


1.0


10.0 Glucosyl naringin active (mg/mL)


Figure 4: The amount of elastin in NHDF treated with or without glucosyl naringin active. N=5, Mean + SD, **p<0.01 vs. control (Dunnett’s test)


was measured using the elastin assay kit. The elastin production in NHDF was significantly increased by the treatment (Figure 4). Additionally, 3D skin models were used to


examine the effects on elastin production. The 3D skin models were reconstructed by building the epidermal layer on top of the constructed dermal layer. Immunostainings were performed


C ** **


Control Control B 0.5mg/mL glucosyl naringin active 5.0mg/mL glucosyl naringin active


0.5


5.0 Glucosyl naringin active (mg/mL) D **


35 30 25 20 15 10 5 0


**


Control


0.5


5.0 Glucosyl naringin active (mg/mL)


Figure 5: Elastin and fibrillin-1 expression in 3D construct treated with or without glucosyl naringin active. A) Immunofluorescence images of elastin (red) and nucleus (blue). Scale bar: 50 µm. B) Immunofluorescence images of fibrillin-1 (green) and nucleus (blue). Scale bar: 50 µm. C, D) Elastin and fibrillin-1 expression level. N=3, Mean + SD, **p<0.01 (Tukey-Kramer test)


PERSONAL CARE September 2023 www.personalcaremagazine.com


Fibrillin-1 expression level


Elastin expression level


Elastin (µg/well)


Tropoelastin mRNA expression level relative to control


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105